Abstract
Overview
Introduction
In the US, approximately 88 million people are diagnosed with a respiratory
tract infection in an average year. Of these, a total of 66 million patients
suffer from one of the three major diagnoses: acute bacterial sinusitis (ABS),
acute exacerbation of chronic bronchitis (AECB) and community-acquired
pneumonia (CAP).
Scope
- Diagnosis patterns of the three conditions: ABS, AECB and CAP, based on a
survey of 90 physicians across the US
- Analysis of treatment regimens and preferences for ABS, AECB and CAP,
according to Datamonitor' s primary research data
- Ranking of the greatest areas of unmet need for diagnostics and
therapeutics within the RTI market
- Evaluation of the reasons underlying prescription choices; discussion of
the differences between diagnoses
Report Highlights
According to Datamonitor research, 83-97% of patients diagnosed with RTIs
receive antibiotic therapy regardless whether a bacterial pathogen could be
identified or not. While beta lactams are preferred for ABS, newer macrolides
and fluoroquinolones are routinely chosen to treat AECB and CAP.
The lack of quick and reliable laboratory tests to identify the underlying
pathogen results in 68-80% of treatments to be initiated empirically. About
16% of patients across the three conditions fail first-line treatment and move
on to second line, mostly due to a lack of coverage for and drug resistance of
the causative organisms.
While physicians appear evenly divided between branded and generic drugs when
prescribing for initially relatively benign conditions such as ABS and AECB,
they strongly prefer newer, more expensive drugs both for more serious
conditions such as CAP and when experiencing treatment failure of their
initial drug choice.
Reasons to Purchase
- Identify the key factors that influence prescribing patterns for US RTI
pharmacotherapy
- Examine the remaining and emerging unmet needs in the US RTI market and
identify opportunities for new product development
- Enhance your commercial positioning through an improved understanding of
the US RTI market dynamics
View Cart
